• Histologically confirmed diagnosis of CD19+ ALL, CD19+ NHL, or BCMA+ MM per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (2020.v2);

• Relapsed or refractory B cell hematological malignancies (meeting one of the following conditions):

‣ CR not achieved after standardized chemotherapy;

⁃ CR achieved following the first induction, but CR duration is less than 12 months;

⁃ Ineffectively after first or multiple remedial treatments;

⁃ 2 or more relapses;

⁃ Relapse after hematopoietic stem cell transplantation;

⁃ Extramedullary leisions which were ineffective to radiotherapy or chemotherapy;

• Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;

• Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;

• No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;

• Estimated survival time ≥ 12 weeks;

• ECOG performance status 0 to 2;

• Women of childbearing age had negative pregnancy test during screening period and before administration, and agreed to take effective contraceptive measures at least one year after infusion.

• Patients volunteer to participate in the study and sign the informed consent.